dihydroxyphenylalanine has been researched along with Tremor in 129 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
Tremor: Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The brain lesion technique was used to investigate the role of the paleostriatum and the nigro-neostriatum in harmine-induced tremor and in its antagonism by dopaminergic agonists, apomorphine, 1-dopa, piribedil, d- and l-amphetamine." | 7.65 | The importance of extrapyramidal function for the induction and antagonism of harmine tremor. ( Kelly, DM; Naylor, RJ, 1975) |
| "Drugs which reduce central catecholamine activity increased the tremorigenic action physostigmine (0." | 7.65 | Modification of the tremorigenic activity of physostigmine. ( Ambrani, LM; Van Woert, MH, 1972) |
| " Seven months later he developed a left rest tremor associated with mild bilateral extrapyramidal symptoms and responsive to levodopa treatment." | 3.69 | Rest tremor and extrapyramidal symptoms after midbrain haemorrhage: clinical and 18F-dopa PET evaluation. ( Defer, GL; Degos, JD; Malapert, D; Remy, P; Ricolfi, F; Samson, Y, 1994) |
| "The brain lesion technique was used to investigate the role of the paleostriatum and the nigro-neostriatum in harmine-induced tremor and in its antagonism by dopaminergic agonists, apomorphine, 1-dopa, piribedil, d- and l-amphetamine." | 3.65 | The importance of extrapyramidal function for the induction and antagonism of harmine tremor. ( Kelly, DM; Naylor, RJ, 1975) |
| "Either L-dopa, in combination with 1-alpha-methyldopa hydrazine (MK-486), or 1-(2''-pyrimidyl)-4-piperonylpiperazine, an agent that stimulates dopamine receptors, relieves surgically induced tremor in monkeys and concomitantly evokes involuntary movements." | 3.65 | Tremor and involuntary movements in monkeys: effect of L-dopa and of a dopamine receptor stimulating agent. ( Anagnoste, B; Battista, AF; Fuxe, K; Goldstein, M; Ohmoto, T, 1973) |
| "Drugs which reduce central catecholamine activity increased the tremorigenic action physostigmine (0." | 3.65 | Modification of the tremorigenic activity of physostigmine. ( Ambrani, LM; Van Woert, MH, 1972) |
| " Hence we would advise that if for any reason anticholinergic drugs are to be withdrawn in patients receiving a stable dosage of levodopa this must be done slowly." | 2.64 | Levodopa in Parkinsonism: the effects of withdrawal of anticholinergic drugs. ( Hughes, RC; Polgar, JG; Walton, JN; Weightman, D, 1971) |
| "Two subjects presented with action tremor around age 10-12 years and developed tremor-dominant parkinsonism with prominent neuropsychiatric features later in their 20s." | 1.72 | WARS2 mutations cause dopa-responsive early-onset parkinsonism and progressive myoclonus ataxia. ( Berutti, R; Bonifati, V; Boumeester, V; Brunet, T; Gdovinova, Z; Han, V; Havrankova, P; Houlden, H; Jech, R; Kaiyrzhanov, R; Kuipers, DJS; Kulcsarova, K; Lackova, A; Mandemakers, W; Orec, L; Ostrozovicova, M; Pavelekova, P; Plecko, B; Rektorova, I; Rizig, M; Skorvanek, M; Steinfeld, R; Tijssen, MAJ; Wagner, M; Winkelmann, J; Zech, M, 2022) |
| "This tremor was refractory to gabapentin and dramatically responded to Levodopa administration." | 1.34 | Dopa-responsive pseudo-orthostatic tremor in parkinsonism. ( Antonini, A; Barone, P; Bonanni, L; Onofrj, M; Thomas, A, 2007) |
| "A series of 203 patients with primary Parkinson's disease treated with L-DOPA, with adequate neurological documentation of mental status at serial intervals during their illness, constitutes the study population." | 1.27 | Dementia in idiopathic Parkinson's disease. Variables associated with its occurrence in 203 patients. ( Elizan, TS; Maker, H; Smith, H; Sroka, H; Yahr, MD, 1986) |
| "Twenty-seven patients with Parkinson's disease participated in a double-blind crossover trial of L-dopa and amantadine." | 1.25 | Interactions of L-dopa and amantadine in patients with Parkinsonism. ( Cox, B; Danta, G; Schnieden, H; Yuill, GM, 1973) |
| "Six patients diagnosed as Parkinson's disease on a clinical basis alone are described, and their response to L-dopa and to alpha methyl dopa hydrazine (MK 486) and L-dopa." | 1.25 | An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy. ( Mones, RJ, 1973) |
| "In monkeys with resting tremor, the administration of DL-5-HTP (5-hydroxytryptophan) or of DL-DOPA (3,4-dihydroxyphenylalanine) relieves the tremor, but the simultaneous administration of DL-5-HTP or DL-DOPA and atropine results in a much more pronounced relief." | 1.25 | The effects of centrally acting drugs on tremor in monkeys with mesencephalic lesions. ( Anagnoste, B; Battista, AF; Goldstein, M; Nakatani, S, 1969) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 116 (89.92) | 18.7374 |
| 1990's | 7 (5.43) | 18.2507 |
| 2000's | 3 (2.33) | 29.6817 |
| 2010's | 2 (1.55) | 24.3611 |
| 2020's | 1 (0.78) | 2.80 |
| Authors | Studies |
|---|---|
| Skorvanek, M | 1 |
| Rektorova, I | 1 |
| Mandemakers, W | 1 |
| Wagner, M | 1 |
| Steinfeld, R | 1 |
| Orec, L | 1 |
| Han, V | 1 |
| Pavelekova, P | 1 |
| Lackova, A | 1 |
| Kulcsarova, K | 1 |
| Ostrozovicova, M | 1 |
| Gdovinova, Z | 1 |
| Plecko, B | 1 |
| Brunet, T | 1 |
| Berutti, R | 1 |
| Kuipers, DJS | 1 |
| Boumeester, V | 1 |
| Havrankova, P | 1 |
| Tijssen, MAJ | 1 |
| Kaiyrzhanov, R | 1 |
| Rizig, M | 1 |
| Houlden, H | 1 |
| Winkelmann, J | 1 |
| Bonifati, V | 1 |
| Zech, M | 1 |
| Jech, R | 1 |
| Pikstra, ARA | 1 |
| van der Hoorn, A | 1 |
| Leenders, KL | 1 |
| de Jong, BM | 1 |
| Asakawa, T | 1 |
| Sugiyama, K | 1 |
| Akamine, S | 1 |
| Yokoyama, C | 1 |
| Shukuri, M | 1 |
| Mizuma, H | 1 |
| Tsukada, H | 1 |
| Onoe, H | 1 |
| Namba, H | 1 |
| Ghaemi, M | 1 |
| Raethjen, J | 1 |
| Hilker, R | 1 |
| Rudolf, J | 1 |
| Sobesky, J | 1 |
| Deuschl, G | 1 |
| Heiss, WD | 1 |
| STERN, P | 3 |
| PRZIC, R | 1 |
| ZEC, N | 1 |
| ROOS, BE | 1 |
| STEG, G | 1 |
| HIRSCHMANN, J | 1 |
| MAYER, K | 1 |
| HANSSON, E | 1 |
| FLEMING, RM | 1 |
| CLARK, WG | 1 |
| Thomas, A | 1 |
| Bonanni, L | 1 |
| Antonini, A | 1 |
| Barone, P | 1 |
| Onofrj, M | 1 |
| Defer, GL | 1 |
| Remy, P | 1 |
| Malapert, D | 1 |
| Ricolfi, F | 1 |
| Samson, Y | 1 |
| Degos, JD | 1 |
| Otsuka, M | 1 |
| Ichiya, Y | 1 |
| Kuwabara, Y | 1 |
| Hosokawa, S | 1 |
| Sasaki, M | 1 |
| Yoshida, T | 1 |
| Fukumura, T | 1 |
| Masuda, K | 1 |
| Kato, M | 1 |
| Katayama, Y | 1 |
| Thobois, S | 1 |
| Guillouet, S | 1 |
| Broussolle, E | 1 |
| Carlsson, A | 1 |
| Kelly, DM | 1 |
| Naylor, RJ | 1 |
| Brooks, DJ | 3 |
| Playford, ED | 1 |
| Ibanez, V | 1 |
| Sawle, GV | 1 |
| Thompson, PD | 1 |
| Findley, LJ | 1 |
| Marsden, CD | 3 |
| Barkhatova, VP | 1 |
| Ivanova-Smolenskaia, IA | 1 |
| Elizan, TS | 1 |
| Sroka, H | 1 |
| Maker, H | 1 |
| Smith, H | 1 |
| Yahr, MD | 2 |
| Van Sande, M | 1 |
| Caers, J | 1 |
| Lowenthal, A | 1 |
| Mozzis, CE | 1 |
| Prange, AJ | 1 |
| Hall, CD | 1 |
| Weiss, EA | 1 |
| Agnoli, A | 1 |
| Casacchia, M | 1 |
| Ruggieri, S | 1 |
| Volante, F | 1 |
| Accornero, N | 1 |
| Lavy, S | 1 |
| Abramsky, O | 1 |
| Carmon, A | 1 |
| Yaar, I | 1 |
| Feldman, S | 1 |
| Coppen, A | 1 |
| Metcalfe, M | 1 |
| Carroll, JD | 1 |
| Morris, JG | 1 |
| Kissel, P | 1 |
| Tridon, P | 1 |
| André, JM | 1 |
| Parkes, JD | 2 |
| Rees, JE | 2 |
| Pinder, RM | 1 |
| van Beek, MC | 1 |
| Timmerman, H | 1 |
| Godwin-Austen, RB | 1 |
| Tomlinson, EB | 1 |
| Frears, CC | 1 |
| Kok, HW | 1 |
| Dumont, M | 1 |
| Lamarre, Y | 1 |
| Birkmayer, W | 3 |
| Rondot, P | 2 |
| Dumas, RJ | 1 |
| Bernheimer, H | 1 |
| Hornykiewicz, O | 2 |
| Jellinger, K | 1 |
| Seitelberger, F | 1 |
| Linauer, W | 1 |
| Mentasti, M | 1 |
| Riederer, P | 1 |
| Poirier, LJ | 3 |
| Jurna, I | 1 |
| Nell, T | 1 |
| Schreyer, I | 1 |
| Larochelle, L | 3 |
| Bédard, P | 2 |
| Sourkes, TL | 2 |
| Martin, WE | 1 |
| Resch, JA | 1 |
| Baker, AB | 1 |
| Watanabe, H | 1 |
| Munakata, H | 1 |
| Chen, SC | 1 |
| Kasuya, Y | 1 |
| Brinkmann, R | 1 |
| Strian, F | 1 |
| Sano, I | 1 |
| Taniguchi, K | 1 |
| Rodríguez, R | 1 |
| Wälzholz, U | 1 |
| Náhunek, K | 1 |
| Svestka, J | 1 |
| Kamenická, V | 1 |
| Rodová, A | 1 |
| Leanderson, R | 1 |
| Meyerson, BA | 2 |
| Persson, A | 1 |
| Fischer, PA | 1 |
| Schneider, E | 1 |
| Jacobi, P | 1 |
| Maxion, H | 1 |
| Laitinen, L | 1 |
| Potvin, AR | 1 |
| Albers, JW | 1 |
| Repa, BS | 1 |
| Henderson, WG | 2 |
| Walker, JE | 1 |
| Stribley, RF | 1 |
| Tourtellotte, WW | 1 |
| Glabb, J | 1 |
| Hübner, W | 1 |
| Glabb, S | 1 |
| Velasco, F | 1 |
| Velasco, M | 1 |
| Metzel, E | 1 |
| Rosati, G | 1 |
| Agnetti, V | 1 |
| Mura, F | 1 |
| Granieri, E | 1 |
| Iivanainen, M | 2 |
| Stern, PH | 1 |
| McDowell, F | 1 |
| Miller, JM | 1 |
| Robinson, MB | 1 |
| Goldstein, M | 7 |
| Battista, AF | 6 |
| Ohmoto, T | 1 |
| Anagnoste, B | 5 |
| Fuxe, K | 2 |
| Ungerstedt, U | 1 |
| Battista, A | 1 |
| Ogawa, M | 2 |
| Meyerson, B | 1 |
| Ambrani, LM | 1 |
| Van Woert, MH | 1 |
| Wycis, HT | 2 |
| Cernacek, J | 1 |
| Brezny, I | 1 |
| Jagr, J | 1 |
| Girard, PF | 1 |
| Trillet, M | 1 |
| Kopp, N | 1 |
| Ansari, KA | 1 |
| Webster, D | 1 |
| Manning, N | 1 |
| Schwab, RS | 2 |
| Poskanzer, DC | 1 |
| England, AC | 1 |
| Young, RR | 2 |
| Cox, B | 1 |
| Danta, G | 1 |
| Schnieden, H | 1 |
| Yuill, GM | 1 |
| Mones, RJ | 1 |
| Kofman, OS | 1 |
| Klawans, HL | 1 |
| Ringel, SP | 1 |
| Van Buren, JM | 1 |
| Li, CL | 1 |
| Shapiro, DY | 1 |
| Sadowsky, DA | 1 |
| Horst, WD | 1 |
| Pool, WR | 1 |
| Spiegel, HE | 1 |
| Knutsson, E | 1 |
| Mårtensson, A | 1 |
| Risberg, AM | 1 |
| Vignalou, J | 1 |
| Beck, H | 2 |
| Paulson, GW | 1 |
| Srebocan, S | 1 |
| Cvetnić, S | 1 |
| Brmalj, V | 1 |
| Fujieda, T | 1 |
| Yamauchi, T | 1 |
| Takahashi, S | 1 |
| Moroji, T | 1 |
| Lieberman, AN | 1 |
| Chase, TN | 1 |
| Woods, AC | 1 |
| Glaubiger, GA | 1 |
| Curzon, G | 1 |
| Kantamaneni, BD | 1 |
| Knill-Jones, R | 1 |
| Akbar, A | 1 |
| Das, S | 1 |
| Kataria, M | 1 |
| Derkach, P | 1 |
| Bieger, D | 1 |
| Borgman, RJ | 1 |
| Baylor, MR | 1 |
| McPhillips, JJ | 1 |
| Stitzel, RE | 1 |
| Bauer, RB | 1 |
| McHenry, JT | 1 |
| Cotzias, GC | 1 |
| Papavasiliou, PS | 1 |
| Gellene, R | 1 |
| Rinne, UK | 1 |
| Sonninen, V | 1 |
| Sugita, K | 1 |
| Mutsuga, N | 1 |
| Takaoka, Y | 1 |
| Takeda, A | 1 |
| Muenter, MD | 1 |
| Ahmad, R | 1 |
| Gillingham, FJ | 1 |
| Hanieh, A | 1 |
| Pullar, IA | 1 |
| Weddell, J | 1 |
| Ashcroft, G | 1 |
| Velasco Suárez, MM | 1 |
| Escobedo, FR | 1 |
| Lipman, IJ | 1 |
| Boudin, G | 1 |
| Castaigne, P | 1 |
| Lhermitte, F | 1 |
| Guillard, A | 1 |
| Marteau, R | 1 |
| Pepin, B | 1 |
| Raphy, B | 1 |
| Webster, DD | 2 |
| Fujita, S | 1 |
| Cooper, IS | 2 |
| Mann, DC | 1 |
| Pearce, LA | 1 |
| Waterbury, LD | 1 |
| McMasters, RE | 1 |
| Reef, HE | 1 |
| Joffe, R | 1 |
| Milletz, H | 1 |
| Giuffrè, R | 2 |
| Gambacorta, D | 1 |
| Selby, G | 1 |
| Nakatani, S | 4 |
| Goldberger, ME | 1 |
| Growden, JH | 1 |
| Rosenstock, HA | 1 |
| Simons, DG | 1 |
| Meyer, JS | 1 |
| Critchley, E | 1 |
| McLellan, DL | 1 |
| Silfverskiöld, BP | 1 |
| Plotnikoff, NP | 1 |
| Kastin, AJ | 1 |
| Anderson, MS | 1 |
| Schally, AV | 1 |
| Guggenheim, MA | 1 |
| Couch, JR | 1 |
| Weinberg, W | 1 |
| Guidetti, B | 1 |
| Wajsbort, J | 1 |
| Hemli, JA | 1 |
| Alfandary, I | 1 |
| Yahel, M | 1 |
| Siegfried, J | 1 |
| Hartmann-von Monakow, K | 2 |
| Restak, R | 1 |
| O'Reilly, S | 1 |
| Hadzović, S | 1 |
| Ernst, AM | 1 |
| Tzavellas, O | 1 |
| Umbach, W | 1 |
| Stellar, S | 1 |
| Mandell, S | 1 |
| Waltz, JM | 1 |
| Völler, GW | 1 |
| Dietrichson, P | 1 |
| Sacks, OW | 1 |
| Messeloff, CR | 1 |
| Schwartz, WF | 1 |
| Postma, JU | 1 |
| Stam, FC | 1 |
| Meerlo, HJ | 1 |
| Römer, F | 1 |
| Bettag, W | 1 |
| Bock, WJ | 1 |
| Hughes, RC | 1 |
| Polgar, JG | 1 |
| Weightman, D | 1 |
| Walton, JN | 1 |
| Duvoisin, RC | 1 |
| Schear, MJ | 1 |
| Barrett, RE | 1 |
| Hoehn, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adenosine A2A Blockade With KW-6002 in Parkinson's Disease[NCT00006337] | Phase 2 | 16 participants | Interventional | 2000-10-31 | Completed | ||
| Effect of Antiglutamatergic Treatment in Parkinson's Disease[NCT00013624] | Phase 2 | 20 participants | Interventional | 2001-03-31 | Completed | ||
| Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease[NCT00006077] | Phase 2 | 50 participants | Interventional | 2000-08-31 | Completed | ||
| Effect of Serotoninergic Treatment in Parkinson's Disease[NCT00009048] | Phase 2 | 30 participants | Interventional | 2001-01-31 | Completed | ||
| Levetiracetam Treatment of L-dopa Induced Dyskinesias[NCT00076674] | Phase 2 | 40 participants | Interventional | 2004-01-31 | Completed | ||
| AMPA Receptor Blockade With LY300164 in the Treatment of Parkinson's Disease[NCT00004576] | Phase 2 | 20 participants | Interventional | 2000-02-29 | Completed | ||
| Prognostic Value of FP-CIT-SPECT in Patients With Parkinson´s Disease[NCT01038310] | 25 participants (Actual) | Observational | 2010-01-31 | Completed | |||
| Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551] | Phase 3 | 223 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from Baseline at Week 8 | Change from Baseline at Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| ADS-5102 1A | 41.8 | 1.2 | 1.6 | 4.8 | 7.5 | 13.2 | 8.8 | 11.7 | 11.3 | 11.4 |
| ADS-5102 Group 1P | 45.6 | -2.8 | -1.4 | 1.5 | -0.4 | 2.6 | 2.6 | 7.3 | 3.7 | 3.7 |
| ADS-5102 Group 2 | 52.8 | 0.8 | 5.7 | 6.5 | 1.6 | 6.1 | 6.1 | 9.4 | 6.4 | 6.5 |
| ADS-5102 Group 3 | 52.4 | -5.3 | -5.2 | -5.3 | -4.8 | -4.6 | -4.6 | -4.9 | 0.9 | 4.1 |
"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change in Baseline from Week 8 | Change in Baseline from Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| Group 1a | 6.5 | -0.2 | -0.8 | -0.3 | 0.0 | 0.2 | 0.4 | 0.9 | 0.4 | 0.4 |
| Group 1P | 9.6 | -3.4 | -3.2 | -3.3 | -2.8 | -2.9 | -3.3 | -2.9 | -2.8 | -2.4 |
| Group 2 | 9.8 | -3.6 | -1.1 | -1.4 | -2.9 | -2.5 | -1.9 | -2.7 | -3.7 | -3.6 |
| Group 3 | 10.4 | -4.0 | -3.9 | -4.4 | -4.7 | -3.6 | -2.5 | -3.7 | -4.3 | -3.6 |
The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AE | Study drug-related AE | SAEs | Permanent discontinuation due to AE | Permanent discontinuation due to drug-related AE | Mild AEs | Moderate AEs | Mild drug-related AE | Moderate drug-related AE | Severe drug-related AE | |
| Group 1a | 57 | 31 | 16 | 12 | 4 | 12 | 25 | 16 | 12 | 3 |
| Group 1P | 70 | 45 | 21 | 21 | 15 | 13 | 36 | 15 | 23 | 7 |
| Group 2 | 23 | 16 | 6 | 6 | 4 | 3 | 13 | 3 | 12 | 1 |
| Group 3 | 55 | 32 | 17 | 10 | 8 | 11 | 26 | 5 | 22 | 5 |
8 reviews available for dihydroxyphenylalanine and Tremor
| Article | Year |
|---|---|
[Functional neurosurgery with an implantable and programmable pulse-generator: control of involuntary movement disorders].
Topics: Brain; Dihydroxyphenylalanine; Electric Stimulation; Electrodes, Implanted; Humans; Movement Disorde | 1997 |
Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
Topics: Aging; Animals; Antiparkinson Agents; Basal Ganglia; Brain Tissue Transplantation; Cell Transplantat | 2001 |
Monoamine precursors and analogues.
Topics: 5-Hydroxytryptophan; Animals; Biogenic Amines; Dihydroxyphenylalanine; Dopamine beta-Hydroxylase; Dr | 1975 |
The pharmacotherapy of Parkinsonism.
Topics: Acetylcholine; Antiparkinson Agents; Atropa belladonna; Brain; Dihydroxyphenylalanine; Dopamine; His | 1972 |
Quantitative evaluation of neuropharmacological trials.
Topics: Activities of Daily Living; Age Factors; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanin | 1974 |
[Treatment of Parkinson's syndrome using L-dopa. 2].
Topics: Adult; Aged; Arrhythmias, Cardiac; Dihydroxyphenylalanine; Electrocardiography; Electromyography; Ha | 1973 |
L-dopa therapy in Parkinson's disease.
Topics: Delirium; Depression; Dihydroxyphenylalanine; Gastrointestinal Hemorrhage; Hallucinations; Humans; H | 1971 |
The shaking patient and advances in the therapy of Parkinsonism.
Topics: Adult; Aged; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Parkinson Disease; Tremor; U | 1971 |
27 trials available for dihydroxyphenylalanine and Tremor
| Article | Year |
|---|---|
Levodopa and L-tryptophan therapy in Parkinsonism.
Topics: Aged; Depression; Dihydroxyphenylalanine; Female; Gait; Homovanillic Acid; Humans; Hydroxyindoleacet | 1972 |
Letter: Levodopa-propranolol therapy in parkinsonian tremor.
Topics: Blood-Brain Barrier; Dihydroxyphenylalanine; Drug Synergism; Drug Therapy, Combination; Humans; Neur | 1974 |
Letter: Propranolol in Parkinson's disease.
Topics: Dihydroxyphenylalanine; Drug Evaluation; Drug Therapy, Combination; Humans; Parkinson Disease; Place | 1974 |
Effects of L-dopa in Parkinson's disease.
Topics: Clinical Trials as Topic; Dihydroxyphenylalanine; Humans; Parkinson Disease; Placebos; Tremor | 1969 |
[10 years of L-DOPA therapy of Parkinson's syndrome].
Topics: Administration, Oral; Amphetamine; Animals; Brain Chemistry; Catecholamines; Clinical Trials as Topi | 1971 |
[2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
Topics: Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Dermatitis, Seborrheic; Dihydroxyphenylalanin | 1974 |
[Management of Parkinson's syndrome using levadopa. Results of a long-term study].
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Clinical Trials as Topic; Depression; Dihyd | 1972 |
Preliminary clinical experience with L-dopa in endogenous depressions.
Topics: Clinical Trials as Topic; Depression; Dihydroxyphenylalanine; Evaluation Studies as Topic; Female; H | 1972 |
Quantitative evaluation of neuropharmacological trials.
Topics: Activities of Daily Living; Age Factors; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanin | 1974 |
A quantitative evaluation of the effects of L-dopa on Parkinson's disease.
Topics: Arm; Clinical Trials as Topic; Dihydroxyphenylalanine; Humans; Movement; Movement Disorders; Muscle | 1973 |
[Treatment of Parkinsonic syndrome with levo-Dopa. Case reports].
Topics: Arteriosclerosis; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Evaluation; Female; Humans; | 1974 |
KR 339 in the treatment of Parkinsonian tremor.
Topics: Aged; Amantadine; Antiparkinson Agents; Blood Sedimentation; Bridged-Ring Compounds; Clinical Trials | 1974 |
[Kr 339 in the treatment of parkinsonian tremor].
Topics: Aged; Amantadine; Antiparkinson Agents; Bridged-Ring Compounds; Clinical Trials as Topic; Dihydroxyp | 1974 |
Levodopa therapy effects on natural history of Parkinsonism.
Topics: Adult; Aged; Dihydroxyphenylalanine; Evaluation Studies as Topic; Humans; Long-Term Care; Middle Age | 1972 |
Parkinson disease treated with a suspected dopamine receptor agonist.
Topics: Adult; Aged; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benztropine; Dihydroxyphenyla | 1974 |
Comparison of amantadine, placebo, and levodopa in Parkinson's disease.
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Evaluation Studies as Topic; Female; Humans; Male; Middle | 1974 |
Experimental treatment of parkinsonism with L-Dopa.
Topics: Clinical Trials as Topic; Dihydroxyphenylalanine; Humans; Parkinson Disease; Placebos; Tremor | 1968 |
A double blind study of 1-dopa treatment in Parkinson's disease.
Topics: Blood Pressure; Clinical Trials as Topic; Dihydroxyphenylalanine; Extrapyramidal Tracts; Female; Hum | 1968 |
[Effects of L-dopa and stereotaxic surgery in Parkinsonism].
Topics: Adult; Aged; Clinical Trials as Topic; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Mo | 1970 |
Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease.
Topics: Clinical Trials as Topic; Dihydroxyphenylalanine; Disability Evaluation; Humans; Male; Mental Proces | 1970 |
[Treatment of Parkinson's disease with L-dopa. 77 cases].
Topics: Adult; Age Factors; Aged; Cardiovascular Diseases; Clinical Trials as Topic; Dihydroxyphenylalanine; | 1970 |
Quantitative measurements of L-dopa therapy in Parkinson's disease.
Topics: Clinical Trials as Topic; Dihydroxyphenylalanine; Disability Evaluation; Follow-Up Studies; Humans; | 1970 |
Effects of L-dopa on the H-reflex in parkinsonism.
Topics: Adult; Aged; Chronaxy; Clinical Trials as Topic; Dihydroxyphenylalanine; Electric Stimulation; Femal | 1971 |
Amantadine for Parkinson's disease.
Topics: Aged; Amantadine; Amines; Brain; Clinical Trials as Topic; Dihydroxyphenylalanine; Disability Evalua | 1971 |
Treatment of severe parkinsonism with L-dopa.
Topics: Clinical Trials as Topic; Dihydroxyphenylalanine; Female; Humans; Hypotension; Male; Middle Aged; Pa | 1971 |
A preliminary report of Australian trials with L-dopa.
Topics: Activities of Daily Living; Adult; Aged; Australia; Brain; Clinical Trials as Topic; Depression; Dih | 1971 |
Levodopa in Parkinsonism: the effects of withdrawal of anticholinergic drugs.
Topics: Dihydroxyphenylalanine; Drug Synergism; Drug Tolerance; Female; Humans; Male; Methods; Neurologic Ma | 1971 |
95 other studies available for dihydroxyphenylalanine and Tremor
| Article | Year |
|---|---|
WARS2 mutations cause dopa-responsive early-onset parkinsonism and progressive myoclonus ataxia.
Topics: Ataxia; Dihydroxyphenylalanine; Humans; Mutation; Myoclonus; Parkinsonian Disorders; Phenotype; Spin | 2022 |
Relation of 18-F-Dopa PET with hypokinesia-rigidity, tremor and freezing in Parkinson's disease.
Topics: Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Female; Humans; Hypokinesia; Male; Parkinson Dise | 2016 |
The food reaching test: a sensitive test of behavioral improvements by deep brain stimulation in MPTP-treated monkey.
Topics: Animals; Carbon Radioisotopes; Cocaine; Corpus Striatum; Deep Brain Stimulation; Dihydroxyphenylalan | 2012 |
Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study.
Topics: Adult; Aged; Brain; Cerebellum; Dihydroxyphenylalanine; Dominance, Cerebral; Energy Metabolism; Fema | 2002 |
A contribution to the therapy of the intentional tremor.
Topics: Dihydroxyphenylalanine; Humans; Hydralazine; Salicylates; Tremor | 1962 |
[The treatment of diseases accompanied by intention tremor symptoms (Preliminary report)].
Topics: Antihypertensive Agents; Dihydroxyphenylalanine; Hepatolenticular Degeneration; Humans; Multiple Scl | 1963 |
THE EFFECT OF L-3, 4-DIHYDROXYPHENYLALANINE AND DL-5-HYDROXYTRYPTOPHAN ON RIGIDITY AND TREMOR INDUCED BY RESERPINE, CHLORPROMAZINE AND PHENOXYBENZAMINE.
Topics: 5-Hydroxytryptophan; Amino Acids; Chlorpromazine; Dihydroxyphenylalanine; Dopamine; Inulin; Movement | 1964 |
[ON THE CONTROL OF AKINESIA AND OTHER EXTRAPYRAMIDAL MOTOR DISORDERS WITH L-DOPA (L-DIHYDROXYPHENYLALANINE)].
Topics: Chorea; Dihydroxyphenylalanine; Electromyography; Extrapyramidal Tracts; Humans; Levodopa; Monoamine | 1964 |
EFFECT OF SOME BENZYLHYDRAZINES AND BENZYLOXYAMINES ON DOPA AND 5-HYDROXYTRYPTOPHAN DECARBOXYLASE IN VIVO.
Topics: 5-Hydroxytryptophan; Amines; Aromatic-L-Amino-Acid Decarboxylases; Carbon Isotopes; Carboxy-Lyases; | 1964 |
Dopa-responsive pseudo-orthostatic tremor in parkinsonism.
Topics: Adult; Dihydroxyphenylalanine; Dopamine Agents; Female; Humans; Male; Middle Aged; Parkinsonian Diso | 2007 |
Rest tremor and extrapyramidal symptoms after midbrain haemorrhage: clinical and 18F-dopa PET evaluation.
Topics: Adult; Basal Ganglia Diseases; Dihydroxyphenylalanine; Electromyography; Fluorine Radioisotopes; Hum | 1994 |
Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms.
Topics: Adult; Aged; Caudate Nucleus; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Humans; Male; | 1996 |
The importance of extrapyramidal function for the induction and antagonism of harmine tremor.
Topics: Alkaloids; Animals; Brain; Caudate Nucleus; Dihydroxyphenylalanine; Extrapyramidal Tracts; Globus Pa | 1975 |
Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study.
Topics: Adult; Aged; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Fluorine Radioisotopes; Humans; Levo | 1992 |
Detection of preclinical Parkinson's disease with PET.
Topics: Adult; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; Diseases in Twins; Dopamine; Female | 1991 |
Detection of preclinical Parkinson's disease with PET.
Topics: Adult; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; Diseases in Twins; Dopamine; Female | 1991 |
[Catecholamine metabolism in essential tremor].
Topics: Adolescent; Adult; Aged; Brain; Catecholamines; Dihydroxyphenylalanine; Epinephrine; Female; Humans; | 1990 |
Dementia in idiopathic Parkinson's disease. Variables associated with its occurrence in 203 patients.
Topics: Age Factors; Aged; Dementia; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Movement Dis | 1986 |
Cerebrospinal fluid amino acids in extrapyramidal disorders before and after L-DOPA treatment.
Topics: Adult; Aged; Amino Acids; Cerebrospinal Fluid; Cerebrospinal Fluid Proteins; Chromatography, Ion Exc | 1971 |
Inefficacy of tryptophan-pyridoxine in essential tremor.
Topics: Basal Ganglia; Dihydroxyphenylalanine; Drug Synergism; Female; Humans; Male; Parkinson Disease; Pyri | 1971 |
Parkinson's tremor, relief by an antiaminic drug (BC 105). Discussion on the biochemical pathogenesis of Parkinsonian tremor.
Topics: Adult; Aged; Benzocycloheptenes; Dihydroxyphenylalanine; Ergolines; Female; Histamine H1 Antagonists | 1972 |
Certain prediction on the effectiveness of L-DOPA on parkinsonism.
Topics: Age Factors; Dihydroxyphenylalanine; Female; Humans; Male; Parkinson Disease; Time Factors; Tremor | 1973 |
Some benzhydryl derivatives as central dopamine receptor stimulating agents.
Topics: Animals; Apomorphine; Behavior, Animal; Benzyl Compounds; Brain; Chlorpromazine; Dihydroxyphenylalan | 1974 |
Experimental tremor following CNS lesions in monkeys.
Topics: Animals; Cerebellar Nuclei; Dihydroxyphenylalanine; Disease Models, Animal; Haplorhini; Mesencephalo | 1973 |
[Dopamine and abnormal movements].
Topics: Benserazide; Body Weight; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Therapy, Combination; Electro | 1972 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Recent views on tremors and their treatment.
Topics: Animals; Basal Ganglia; Biogenic Amines; Brain; Brain Diseases; Brain Mapping; Brain Stem; Cerebral | 1970 |
Motor disturbance induced by tremorine and oxotremorine.
Topics: Acetylcholine; Amines; Animals; Atropine; Biperiden; Brain; Bridged-Ring Compounds; Chlorpromazine; | 1970 |
Correlative neuroanatomical and neuropharmacological study of tremor and catatonia in the monkey.
Topics: Animals; Catatonia; Cerebellum; Cerebral Cortex; Dihydroxyphenylalanine; Dopamine; Haplorhini; Human | 1971 |
Juvenile parkinsonism.
Topics: Adult; Age Factors; Aged; Diagnosis, Differential; Dihydroxyphenylalanine; Dopamine; Humans; Male; M | 1971 |
Effect of L-dopa, adrenergic -blockers and anticholinergic agents on the tremorine-tremor in mice.
Topics: Adrenergic beta-Antagonists; Amino Alcohols; Animals; Dihydroxyphenylalanine; Drug Combinations; Hyd | 1971 |
[Apomorphine in the biochemical concept of Parkinson's tremor].
Topics: Animals; Apomorphine; Brain Chemistry; Dihydroxyphenylalanine; Drug Therapy, Combination; Humans; Pa | 1974 |
[L-5-hydroxytryptophan(L-5-HTP) therapy of Parkinson's disease. 2].
Topics: 5-Hydroxytryptophan; Adult; Aged; Depression; Dihydroxyphenylalanine; Female; Humans; Male; Middle A | 1972 |
Antagonism of tremorine-induced tremor by serotoninergic agents in mice. Interactions with levodopa.
Topics: 5-Hydroxytryptophan; Animals; Atropine; Benztropine; Dihydroxyphenylalanine; Dose-Response Relations | 1972 |
Lip muscle function in Parkinsonian Dysarthria.
Topics: Dihydroxyphenylalanine; Electromyography; Facial Muscles; Follow-Up Studies; Humans; Lip; Middle Age | 1972 |
[Longtime study on the effects of L-dopa therapy in parkinsonism].
Topics: Aged; Depression; Dihydroxyphenylalanine; Electromyography; Female; Humans; Male; Middle Aged; Parki | 1973 |
Surgical treatment, past and present, in Parkinson's disease.
Topics: Adult; Aged; Brain; Cordotomy; Dihydroxyphenylalanine; Electrocoagulation; Female; Functional Latera | 1972 |
[Surgical management of parkinsonism].
Topics: Age Factors; Basal Ganglia; Brain; Caudate Nucleus; Cerebellar Nuclei; Corpus Striatum; Dihydroxyphe | 1974 |
Tremor and involuntary movements in monkeys: effect of L-dopa and of a dopamine receptor stimulating agent.
Topics: 5-Hydroxytryptophan; Animals; Benzyl Compounds; Dihydroxyphenylalanine; Dioxoles; Drug Interactions; | 1973 |
Action of m-tyrosine in experimental models: evidence for possible antiparkinsonian activity.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain Chemistry; Denervation; Dihydrox | 1973 |
[Surgical treatment of parkisonism in the light of the modern medical therapy].
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease; Prognosis; Tremor | 1972 |
Modification of the tremorigenic activity of physostigmine.
Topics: Animals; Behavior, Animal; Catecholamines; Chlorpromazine; Dihydroxyphenylalanine; Drug Synergism; M | 1972 |
The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report.
Topics: Antiparkinson Agents; Dibenzazepines; Dihydroxyphenylalanine; Dimethylamines; Drug Synergism; Evalua | 1972 |
[Stabilographic evaluation of anticholinergic and dopaminergic medication in parkinsonism].
Topics: Dihydroxyphenylalanine; Drug Combinations; Female; Humans; Male; Parkinson Disease; Posture; Scopola | 1972 |
[Correction by L-dopa of neurologic manifestations of a chronic portocaval encephalopathy].
Topics: Alcoholism; Ammonia; Brain Diseases; Dihydroxyphenylalanine; Electroencephalography; Humans; Ketoglu | 1972 |
Spasmodic torticollis and L-dopa. Results of therapeutic trial in six patients.
Topics: Dihydroxyphenylalanine; Evaluation Studies as Topic; Head; Humans; Male; Middle Aged; Rotation; Tort | 1972 |
Amantadine in Parkinson's disease. Review of more than two years' experience.
Topics: Aged; Amantadine; Ataxia; Constipation; Depression; Diarrhea; Dihydroxyphenylalanine; Drug Synergism | 1972 |
Interactions of L-dopa and amantadine in patients with Parkinsonism.
Topics: Amantadine; Dihydroxyphenylalanine; Drug Interactions; Evaluation Studies as Topic; Female; Homovani | 1973 |
An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy.
Topics: Aged; Carbidopa; Diagnosis, Differential; Dihydroxyphenylalanine; Evaluation Studies as Topic; Femal | 1973 |
A therapeutic paradox? Combined treatment of Parkinson's disease with levodopa and methyldopa.
Topics: Dihydroxyphenylalanine; Drug Synergism; Evaluation Studies as Topic; Female; Follow-Up Studies; Huma | 1973 |
A clinical study of methysergide in Parkinsonism: evidence against a serotonergic mechanism.
Topics: Adult; Aged; Basal Ganglia; Corpus Striatum; Dihydroxyphenylalanine; Evaluation Studies as Topic; Fe | 1973 |
A qualitative and quantitative evaluation of parkinsonians three to six years following thalamotomy.
Topics: Dihydroxyphenylalanine; Evaluation Studies as Topic; Follow-Up Studies; Humans; Motor Skills; Muscle | 1973 |
Correlation between brain dopamine levels and 1-dopa activity in anti-Parkinson tests.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Blepharoptosis; Brain; | 1973 |
The influence of a previous thalamotomy on the L-dopa effects on mono-manual dexterity in parkinsonism.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Dihydroxyphenylalanine; Female; Functional Lateral | 1973 |
[L-dopa in 122 cases of Parkinson's disease in patients over 70 years old. Comparative study with a group of Parkinsonian patients who are 41 to 69 years old].
Topics: Activities of Daily Living; Adult; Age Factors; Aged; Dihydroxyphenylalanine; Drug Tolerance; Female | 1973 |
Failures of L-dopa.
Topics: Aged; Aging; Depression; Dihydroxyphenylalanine; Humans; Male; Medication Errors; Middle Aged; Movem | 1973 |
[Epidemic tremor in chickens as a model for the testing of antiparkinson drugs].
Topics: Amantadine; Animals; Antiparkinson Agents; Chickens; Dihydroxyphenylalanine; Disease Models, Animal; | 1973 |
Letter: Effect of levodopa on tremor in Benedikt's syndrome.
Topics: Adult; Ataxia; Dihydroxyphenylalanine; Humans; Hyperkinesis; Male; Mesencephalon; Ophthalmoplegia; P | 1974 |
Parkinson's disease: a clinical review.
Topics: Adult; Aged; Brain Diseases; Bulbar Palsy, Progressive; Dementia; Diagnosis, Differential; Dihydroxy | 1974 |
Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa.
Topics: Aged; Dementia; Dihydroxyphenylalanine; Electroencephalography; Female; Gait; Homovanillic Acid; Hum | 1974 |
L-DOPA-chlorpromazine antagonism on running activity in mice.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Body Weight; Chlorpromazine; Dih | 1974 |
Alpha-methyldopamine derivatives. Synthesis and pharmacology.
Topics: Animals; Apomorphine; Blepharoptosis; Body Temperature; Depression, Chemical; Dihydroxyphenylalanine | 1974 |
Akinesis following stereotactic surgery for Parkinsonism. The use of L-dopa.
Topics: Adult; Aged; Dihydroxyphenylalanine; Drug Tolerance; Female; Globus Pallidus; Humans; Male; Middle A | 1970 |
Stereotaxic intracerebral instillation of dopa.
Topics: Caudate Nucleus; Dihydroxyphenylalanine; Electroencephalography; Humans; Methods; Movement Disorders | 1970 |
The therapeutic possibilities of L-dopa and amantadine in Parkinsonian patients who have undergone bilateral thalamotomy.
Topics: Adolescent; Adult; Aged; Amantadine; Child; Dihydroxyphenylalanine; Electroencephalography; Female; | 1971 |
Drug-induced relief of the tremor in monkeys with mesencephalic lesions.
Topics: Animals; Dihydroxyphenylalanine; Disease Models, Animal; Haplorhini; Mesencephalon; Tremor | 1969 |
The effects of centrally acting drugs on tremor in monkeys with mesencephalic lesions.
Topics: 5-Hydroxytryptophan; Animals; Atropine; Dihydroxyphenylalanine; Disease Models, Animal; Drug Synergi | 1969 |
Reversible effect of L-dopa on tremor and catatonia induced by alpha-methyl-p-tyrosine.
Topics: Animals; Catatonia; Dihydroxyphenylalanine; Haplorhini; Humans; Methyltyrosines; Tremor | 1970 |
Drug-induced relief of experimental tremor in monkeys.
Topics: 5-Hydroxytryptophan; Animals; Basal Ganglia; Brain Stem; Dihydroxyphenylalanine; Disease Models, Ani | 1970 |
The effect of DL dopa on harmaline induced tremor and on resting tremor in monkeys with tegmental lesions.
Topics: Alkaloids; Animals; Dihydroxyphenylalanine; Extremities; Haplorhini; Indoles; Injections, Intravenou | 1970 |
Tremor at rest following cerebellar lesions in monkeys: effect of L-DOPA administration.
Topics: Animals; Cerebellar Nuclei; Dihydroxyphenylalanine; Haplorhini; Injections, Intravenous; Tremor | 1971 |
Chronic manganism. Neurologic and laboratory studies during treatment with levodopa.
Topics: Administration, Oral; Adult; Chronic Disease; Dihydroxyphenylalanine; Edetic Acid; Facial Expression | 1971 |
Production of involuntary movements by L-dopa in monkeys with tegmental lesions.
Topics: Animals; Carboxy-Lyases; Dihydroxyphenylalanine; Disease Models, Animal; Haplorhini; Mesencephalon; | 1971 |
Clinical manifestations of essential tremor.
Topics: Adult; Aged; Amantadine; Ataxia; Chlordiazepoxide; Dihydroxyphenylalanine; Female; Humans; Male; Mep | 1972 |
Levodopa in Parkinsonism: reduction in the electromyographic silent period and its relationship with tremor.
Topics: Adult; Aged; Dihydroxyphenylalanine; Electric Stimulation; Electromyography; Female; Humans; Male; M | 1972 |
[Disturbed equilibrium in chronic alcoholism].
Topics: Adult; Alcoholism; Ataxia; Dihydroxyphenylalanine; Electromyography; Gait; Humans; Leg; Movement Dis | 1972 |
Oxotremorine antagonism by a hypothalamic hormone, melanocyte-stimulating hormone release-inhibiting factor (MIF).
Topics: Acetylcholine; Animals; Ataxia; Diarrhea; Dihydroxyphenylalanine; Drug Antagonism; Guinea Pigs; Huma | 1972 |
The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report.
Topics: Antiparkinson Agents; Dibenzazepines; Dihydroxyphenylalanine; Dimethylamines; Humans; Parkinson Dise | 1972 |
Motor dysfunction as a permanent complication of methanol ingestion. Presentation of a case with a beneficial response to levodopa treatment.
Topics: Adolescent; Dihydroxyphenylalanine; Female; Humans; Methanol; Motor Cortex; Movement Disorders; Opti | 1971 |
A year's experience of L-DOPA in the treatment of Parkinson's disease.
Topics: Adult; Age Factors; Aged; Dihydroxyphenylalanine; Female; Functional Laterality; Humans; Hypotension | 1971 |
[Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
Topics: Aged; Benzyl Compounds; Carboxy-Lyases; Dihydroxyphenylalanine; Female; Humans; Hydrazines; Male; Mi | 1971 |
[Treatment of the Parkinson syndrome with amantadine].
Topics: Adult; Aged; Amantadine; Arteriosclerosis; Cognition Disorders; Dihydroxyphenylalanine; Drug Interac | 1971 |
Non-resting tremor in Parkinson's disease.
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Humans; Male; Parkinson Disease; Propranolol; Tremor | 1971 |
Heredofamilial tremor. A case study.
Topics: Dihydroxyphenylalanine; Hand; Handwriting; Humans; Male; Middle Aged; Tremor | 1971 |
The effect of 5-hydroxytryptamine and 5-hydroxytryptophan on extra-pyramidal function.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Basal Ganglia; Behavior, Animal; Dihydroxyphenylalanine; | 1969 |
[Clinical and electromyographic controls of the effect of dopamine in parkinsonian patients].
Topics: Blood Pressure; Dihydroxyphenylalanine; Electroencephalography; Electromyography; Humans; Movement D | 1967 |
Quantitative measurements of L-dopa therapy in Parkinson's disease.
Topics: Aged; Dihydroxyphenylalanine; Facial Expression; Gait; Humans; Male; Middle Aged; Motor Skills; Park | 1969 |
[Therapy of extrapyramidal-motor symptoms. Drug treatment].
Topics: Alkaloids; Atropa belladonna; Dihydroxyphenylalanine; Extrapyramidal Tracts; Humans; Monoamine Oxida | 1969 |
L-dopa in the treatment of Parkinsonism; a preliminary appraisal.
Topics: Adult; Aged; Cryosurgery; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Parkinson Disea | 1970 |
[The treatment of parkinsonism with amantadine].
Topics: Adult; Aged; Amantadine; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Parasympatholyti | 1970 |
Quantitative appraisal of L-dopa in Parkinsonism.
Topics: Dihydroxyphenylalanine; Electromyography; Humans; Parkinson Disease; Spasm; Tremor | 1970 |
Long-term effects of levodopa in the severely disabled patient.
Topics: Chorea; Dihydroxyphenylalanine; Female; Humans; Male; Movement Disorders; Parkinson Disease; Parkins | 1970 |
[Experiences with L-DOPA (Eldopal) treatment of 40 patients with Parkinson's disease].
Topics: Adult; Aged; Dihydroxyphenylalanine; Female; Handwriting; Humans; Male; Middle Aged; Parkinson Disea | 1971 |
[L-dopa effect in Parkinson's syndrome].
Topics: Dihydroxyphenylalanine; Electroencephalography; Humans; Male; Middle Aged; Parkinson Disease; Tremor | 1971 |
Treatment of parkinsonism with levodopa.
Topics: Adult; Aged; Anorexia Nervosa; Arrhythmias, Cardiac; Dihydroxyphenylalanine; Female; Gait; Humans; H | 1969 |